A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people

AIDS

Volumn 24, Issue 18, 2010, Pages 2835-2840

  Bangsberg, David R ^a   Ragland, Kathleen ^b   Monk, Alex ^b   Deeks, Steven G ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adherence; Dosing frequency; Drug use; Homeless; Mental illness; Once daily; One pill; Pill burden

Indexed keywords

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL; VIRUS RNA;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMELESSNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ADENINE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HOMELESS PERSONS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PHOSPHONIC ACIDS; VIRAL LOAD;

EID: 78549267434     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328340a209     Document Type: Article

References (22)

1. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
2. Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of selfreport and electronic monitoring. Clin Infect Dis 2001; 33:1417-1423.
3. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14:357-366.
4. Sontag D, Richardon L. Doctors withhold HIV pill regimen from some. New York Times; 1997:Sect. A1.
5. El-Sadr WM, Mayer KH, Hodder SL. AIDS in America: forgotten but not gone. N Engl J Med 2010; 362:967-970.
6. Molina JM, Podsadecki TJ, Johnson MA, Wilkin A, Domingo P, Myers R, et al. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is noninferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retrovirus 2007; 23:1505-1514.
7. Portsmouth SD, Osorio J, McCormick K, Gazzard BG, Moyle GJ. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med 2005; 6:185-190.
8. Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis 2009; 48:484-488.
9. Tapper ML, Flexner C, Eron JJ, Molina JM. Simplifying antiretroviral therapy. AIDS Read 2004; 14:355-360; 367-371.
10. Boyle BA, Jayaweera D, Witt MD, Grimm K, Maa JF, Seekins DW. Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression. HIV Clin Trials 2008; 9:164-176.
11. Wright D, Rodriguez A, Godofsky E, Walmsley S, Labriola- Tompkins E, Donatacci L, et al. Efficacy and safety of 48 weeks of enfuvirtide 180mg once-daily dosing versus 90mg twicedaily dosing in HIV-infected patients. HIV Clin Trials 2008; 9:73-82.
12. Airoldi M, Zaccarelli M, Bisi L, Bini T, Antinori A, Mussini C, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence 2010; 13:115-125.
13. Bangsberg DR, Acosta EP, Gupta R, Guzman D, Riley ED, Harrigan PR, et al. Adherence-resistance relationships for protease and nonnucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006; 20:223-231.
14. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, Moss A. Nonadherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001; 15:1181-1183.
15. Moss AR, Hahn JA, Perry S, Charlebois ED, Guzman D, Clark RA, Bangsberg DR. Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study. Clin Infect Dis 2004; 39:1190-1198.
16. Beck A, Ward C, Mendelson M. An inventory for measuring depression. Arch Psychiatry 1961; 4:561-567.
17. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006; 43:939-941.
18. Maggiolo F, Ripamonti D, Arici C, Gregis G, Quinzan G, Camacho GA, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clin Trials 2002; 3:371-378.
19. Jayaweera D, Dejesus E, Nguyen KL, Grimm K, Butcher D, Seekins DW. Virologic suppression, treatment adherence, and improved quality of life on a once-daily efavirenz-based regimen in treatment-Naive HIV-1-infected patients over 96 weeks. HIV Clin Trials 2009; 10:375-384.
20. Martin M, Del Cacho E, Codina C, Tuset M, De Lazzari E, Mallolas J, et al. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retrovirus 2008; 24:1263-1268.
21. Street E, Curtis H, Sabin CA, Monteiro EF, Johnson MA. British HIV Association (BHIVA) national cohort outcomes audit of patients commencing antiretrovirals from naive. HIV Med 2009; 10:337-342.
22. DHHS. Guidelines for the use of antiretroviral agents in HIV-1- infected adults and adolescents. Washington, DC: Department of Health and Human Services; 2009.